Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Deciphera Pharmaceuticals, LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Able to take oral medication
If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
Adequate organ function and electrolytes
Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of 0 to 1 at Screening
Has a life expectancy of more than 6 months
Pathologically confirmed diagnosis of solid cancer and documentation of Kirsten rat sarcoma (KRAS), Harvey rat sarcoma virus (HRAS), neuroblastoma ras viral oncogene homolog (NRAS), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), v-raf murine sarcoma viral oncogene homolog C1(CRAF), and/or neurofibromatosis 1 (NF1) mutation
Have exhausted all available standard of care therapies that are known to provide benefit for the participant's condition, as judged by the Investigator
Documented BRAF gene mutation
Pathologically confirmed diagnosis with PD after at least one prior line of therapy in the advanced or metastatic setting
You may not be if
Prior treatment with certain BRAF dimer inhibitors
Female participant is pregnant or lactating
Received any prior or concurrent medications or therapies known to be prohibited with DCC-3084 within 14 days
Received any prior antitumor therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-3084
Known allergy or hypersensitivity to any component of the study drug
Invasive malignancy within 2 years prior to the first dose of study drug other than the study indication or specific types of cancer treated with curative intent
Have not recovered from all clinically relevant toxicities from prior therapy
Impaired cardiac function
History of recent thrombotic or embolic events
Malabsorption syndrome or other illness that could affect oral absorption
Major surgery within 28 days of the first dose of study drug
Has known co-occurring mutation of KRAS, HRAS, NRAS, NF1, epidermal growth factor receptor, Phosphoinositide-3-kinase, catalytic, alpha polypeptide (PI3KCA), or Phosphatase and TENsin homolog deleted on chromosome 10 (PTEN)
